German firm BioNTech warns there is no data backing the “safety and efficacy” of delaying the second shot of its COVID-19 vaccine beyond three weeks, as some countries push back the jab to give more people their first dose.
BioNTech, which developed the vaccine with US giant Pfizer, says its clinical data showing 95 percent efficacy was based on a two-dose schedule separated by 21 days.
“The safety and efficacy of the vaccine has not been evaluated on different dosing schedules,” it says.
“Although data… demonstrated that there is a partial protection from the vaccine as early as 12 days after the first dose, there is no data to demonstrate that protection after the first dose is sustained after 21 days.”
A nurse receives the Pfizer-Biontech coronavirus vaccine at the Helsinki University Hospital in Helsinki, Finland on December 27, 2020 (Alessandro RAMPAZZO / AFP)
Faced with limited supplies of the vaccines, Denmark said Monday it would space out the jabs by up to six weeks, while Britain has said it would wait up to 12 weeks before giving the second jab.
Germany too is mulling pushing back the second shot to beyond 21 days.
— AFP
We can't do this work alone.
The war with Iran has been draining for all of us in Israel. But when I heard about a high casualty incident – ballistic missile impacts in Arad and Dimona that left nearly 200 people wounded – I drank a cup of coffee, packed a bag, and headed south.
There, I spoke with Shilgit, the head of an after-school program for underprivileged youth. Standing outside her destroyed center, Shilgit said it was a miracle that no children were hurt and spoke about the community coming together in the hours since.
As a Times of Israel reporter, I’m committed to telling stories of resilience like Shilgit’s. But my colleagues and I can't do this alone. If you value work like this,please consider joining our reader support group, The Times of Israel Community. Your financial support is essential to keep real human reporting like this going.
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you, David Horovitz, Founding Editor of The Times of Israel
From the Liveblog of
Tuesday, January 5, 2021
